Study of Late Toxicity Biomarkers of Locally Advanced Head and Neck Cancer Patients Treated with Radiotherapy Plus Cisplatin or Cetuximab Points to the Relevance of Skin Macrophages (TOX-TTCC-2015-01)

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2024 May 23

PMID 38782865

Authors

Antonio Rullan

Juan A Marin-Jimenez

Alicia Lozano

Oriol Bermejo

Lorena Arribas

Nuria Ruiz

Isabel Linares

Miren Taberna

Xavi Perez

Maria Plana

Marc Oliva

Ricard Mesia

Affiliations

Soon will be listed here.

Abstract

Purpose: Radiotherapy (RT) with concomitant cisplatin (CRT) or cetuximab (ERT) are accepted treatment options for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). Long-term adverse events (AEs) have a vast impact on patients' quality of life. This study explored tissue biomarkers which could help predict late toxicity.

Methods/patients: Single-institution prospective study including patients aged ≥ 18 with histologically confirmed newly diagnosed LA-SCCHN treated with RT and either concomitant cisplatin q3w or weekly cetuximab, according to institutional protocols. All patients underwent pre- and post-treatment skin biopsies of neck regions included in the clinical target volume. Angiogenesis, macrophages, and extracellular matrix (ECM) markers were evaluated by immunohistochemistry (IHC).

Results: From April 15, 2016, to December 11, 2017; 31 patients were evaluated [CRT = 12 (38.7%) and ERT = 19 (61.3%)]. 27 patients (87%) had received induction chemotherapy. All patients finished RT as planned. IHC expression of vasculature (CD34) and collagen (Masson's Trichrome) did not differ significantly between and within CRT and ERT arms. Conversely, an increased CD68 and CD163 macrophage infiltration expression was observed after treatment, without significant impact of treatment modality. Patients with higher late toxicity showed lower expression of macrophage markers in pre-treatment samples compared with those with lower late toxicity, with statistically significant differences for CD68.

Conclusions: Angiogenesis and ECM biomarkers did not differ significantly between CRT and ERT. Macrophage markers increased after both treatments and deserve further investigation as predictors of late toxicity in LA-SCCHN patients. [Protocol code: TOX-TTCC-2015-01/Spanish registry of clinical studies (REec): 2015-003012-21/Date of registration: 27/01/2016].

References

Ottery F . Definition of standardized nutritional assessment and interventional pathways in oncology. Nutrition. 1996; 12(1 Suppl):S15-9. DOI: 10.1016/0899-9007(96)90011-8. View

Bang C, Bernard G, Le W, Lalonde A, Kadoury S, Bahig H . Artificial intelligence to predict outcomes of head and neck radiotherapy. Clin Transl Radiat Oncol. 2023; 39:100590. PMC: 10014342. DOI: 10.1016/j.ctro.2023.100590. View

Fanetti G, Polesel J, Fratta E, Muraro E, Lupato V, Alfieri S . Prognostic Nutritional Index Predicts Toxicity in Head and Neck Cancer Patients Treated with Definitive Radiotherapy in Association with Chemotherapy. Nutrients. 2021; 13(4). PMC: 8070136. DOI: 10.3390/nu13041277. View

Gillison M, Trotti A, Harris J, Eisbruch A, Harari P, Adelstein D . Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2018; 393(10166):40-50. PMC: 6541928. DOI: 10.1016/S0140-6736(18)32779-X. View

Autio P, Saarto T, Tenhunen M, Elomaa I, Risteli J, Lahtinen T . Demonstration of increased collagen synthesis in irradiated human skin in vivo. Br J Cancer. 1998; 77(12):2331-5. PMC: 2150405. DOI: 10.1038/bjc.1998.387. View

Machtay M, Moughan J, Trotti A, Garden A, Weber R, Cooper J . Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008; 26(21):3582-9. PMC: 4911537. DOI: 10.1200/JCO.2007.14.8841. View

Borrelli M, Shen A, Lee G, Momeni A, Longaker M, Wan D . Radiation-Induced Skin Fibrosis: Pathogenesis, Current Treatment Options, and Emerging Therapeutics. Ann Plast Surg. 2019; 83(4S Suppl 1):S59-S64. PMC: 6746243. DOI: 10.1097/SAP.0000000000002098. View

Machiels J, Leemans C, Golusinski W, Grau C, Licitra L, Gregoire V . Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(11):1462-1475. DOI: 10.1016/j.annonc.2020.07.011. View

Langendijk J, Doornaert P, Verdonck-de Leeuw I, Leemans C, Aaronson N, Slotman B . Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol. 2008; 26(22):3770-6. DOI: 10.1200/JCO.2007.14.6647. View

10.

Ghadjar P, Simcock M, Zimmermann F, Betz M, Bodis S, Bernier J . Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94). Radiother Oncol. 2012; 104(2):213-8. DOI: 10.1016/j.radonc.2012.05.004. View

11.

Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J . Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011; 100(1):33-40. DOI: 10.1016/j.radonc.2011.05.036. View

12.

Bankhead P, Loughrey M, Fernandez J, Dombrowski Y, McArt D, Dunne P . QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017; 7(1):16878. PMC: 5715110. DOI: 10.1038/s41598-017-17204-5. View

13.

Meyer F, Fortin A, Wang C, Liu G, Bairati I . Predictors of severe acute and late toxicities in patients with localized head-and-neck cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2011; 82(4):1454-62. DOI: 10.1016/j.ijrobp.2011.04.022. View

14.

Sumner W, Ray X, Sutton L, Rebibo D, Marincola F, Sanghvi P . Gene alterations as predictors of radiation-induced toxicity in head and neck squamous cell carcinoma. J Transl Med. 2021; 19(1):212. PMC: 8130372. DOI: 10.1186/s12967-021-02876-5. View

15.

Rivelli T, Mak M, Martins R, Torres da Costa E Silva V, de Castro Jr G . Cisplatin based chemoradiation late toxicities in head and neck squamous cell carcinoma patients. Discov Med. 2015; 20(108):57-66. View

16.

Isaksson L, Pepa M, Zaffaroni M, Marvaso G, Alterio D, Volpe S . Machine Learning-Based Models for Prediction of Toxicity Outcomes in Radiotherapy. Front Oncol. 2020; 10:790. PMC: 7289968. DOI: 10.3389/fonc.2020.00790. View

17.

Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T . Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet. 2018; 393(10166):51-60. PMC: 6319250. DOI: 10.1016/S0140-6736(18)32752-1. View

18.

Bordon E, Henriquez-Hernandez L, Lara P, Ruiz A, Pinar B, Rodriguez-Gallego C . Prediction of clinical toxicity in locally advanced head and neck cancer patients by radio-induced apoptosis in peripheral blood lymphocytes (PBLs). Radiat Oncol. 2010; 5:4. PMC: 2827476. DOI: 10.1186/1748-717X-5-4. View

19.

Yarnold J, Brotons M . Pathogenetic mechanisms in radiation fibrosis. Radiother Oncol. 2010; 97(1):149-61. DOI: 10.1016/j.radonc.2010.09.002. View

20.

Taberna M, Rullan A, Hierro C, Navarro V, Vazquez S, Lozano A . Late toxicity after radical treatment for locally advanced head and neck cancer. Oral Oncol. 2015; 51(8):795-9. DOI: 10.1016/j.oraloncology.2015.05.002. View